The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. About Novavax. Novavax, Inc.?(Nasdaq:

Protein 52

Protein Vaccination Vaccine Immune Response 52

The Pharma Data

NOVEMBER 9, 2020

“While the regulatory review of this clinical program will be expedited, Novavax remains committed to a data-driven and scientifically rigorous approach in demonstrating safety and efficacy, which we believe will support confidence in the vaccine in the U.S. and globally.”. and Australia.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. SYNB1891 is being evaluated in a Phase 1 clinical trial.

Immune Response 40

Immune Response Engineer Medicine Clinical Trials 40

Cloudbyz

MARCH 5, 2024

They are often used to mimic or enhance natural biological processes, such as immune responses. Immunogenicity : Small Molecules: Generally have a lower risk of inducing an immune response in the body. Monitoring and managing immunogenicity is a complex aspect of clinical trials for biologics.

Development 97

Development Drugs Immune Response Manufacturing 97

The Pharma Data

NOVEMBER 30, 2020

In alignment with Novavax’ commitment to transparency, Phase 3 clinical trial protocols are posted to the company’s website at Novavax.com/resources upon finalization. pivotal Phase 3 trial update. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinical trial being conducted in the U.K.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

The Pharma Data

JANUARY 6, 2021

Quantitative imaging of CD8 T cells enables quicker identification of drug efficacy, therefore potentially reducing the length of clinical trials, reducing costs and helping new therapies to advance to market faster, which ultimately will improve treatment and care of cancer patients. About ImaginAb. ImaginAb Inc.

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

pharmaphorum

SEPTEMBER 7, 2022

.” Roche’s activity in this area is represented by RG6279, an anti-PD-1 antibody fused to an engineered, variant form of IL-2 which is in phase 1 clinical testing. In 2019, Sanofi bought Synthorx and its IL-2 variant THOR-707 (now renamed SAR44425) for around $2.5

Immune Response 52

Immune Response Engineer Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration were based on mRNA, more conventional protein-based vaccines have also shown promise in clinical trials. Most train the immune system to recognize the RBD, a peptide that is the portion of the SARS-CoV-2 spike protein that binds to the ACE-2 receptor on host cell surfaces.

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

OCTOBER 21, 2020

The active IND enables the Company to initiate the first-in-human clinical trial to assess safety and efficacy of ADI-001 in NHL patients. T cell therapies by Adicet, and marks the beginning of clinical development of a deep pipeline of “off-the-shelf” ?? “We T cell therapy in NHL patients. About Adicet.

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

pharmaphorum

NOVEMBER 2, 2021

In 2019, there were 57 bsAb candidates in clinical trials, against both haematological and solid tumours. The BiTE platform is an innovative technology designed to engage the immune system against numerous stages and types of cancers. Engagement of immune cells to the tumour cell.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

MAY 24, 2024

” XTALKS WEBINAR: AI-based Antibody Therapeutics Developability Assessment and Its Engineering Live and On-Demand: Friday, June 21, 2024, at 10am EDT (4pm CEST/EU-Central) Register for this webinar today to learn how AI can be used to improve developability screening of antibody therapeutics and optimization of antibody candidates.

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

XTalks

DECEMBER 12, 2023

It’s all part of a deep-seated commitment to innovation and its role as the company’s growth engine. Within the next few months we’re expecting topline results from a Phase III clinical trial on a next-generation fibrinogen, an important plasma protein essential for blood clotting.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Cloudbyz

JULY 31, 2024

This includes tracking the persistence and function of modified cells, detecting any adverse immune responses, and ensuring that the therapeutic effects are sustained over time. Personalized Post-Treatment Plans: Post-market diagnostics enable the customization of post-treatment care plans based on individual patient responses.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Freenome persists in getting strong financial support for its development work, with USD 270 million in new funds to push its cancer-detecting blood test via clinical trials and across the FDA’s finish line.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

JANUARY 22, 2021

iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

The Pharma Data

JUNE 25, 2021

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. BARDA is providing up to $1.75

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

OCTOBER 27, 2020

Be Bio plans to use their $52 million Series A to precisely engineer B cells to treat a range of diseases. million Series A gives it the capital to take their PRTX007 candidate into a short-term pharmacokinetic, pharmacodynamic and tolerability study, followed by a clinical proof-of-concept in an acute viral disease setting.

Gene 52

Gene Gene Therapy Medicine Development 52

The Pharma Data

AUGUST 22, 2021

This is how many medical studies begin, said biomedical engineering professor Phil Bourne, who serves as founding dean for the School of Data Science. Typically, to find out whether a drug is effective in treating a particular medical condition, scientists develop prospective clinical trials.

Doctors 52

Doctors Doctor Drugs Scientist 52

The Pharma Data

JULY 6, 2021

It is engineered by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Eloctate to use a naturally occurring pathway to extend the time the therapy remains in the body. The clinical significance of these mechanisms is currently under investigation.

Protein 52

Protein RNA Development Marketing 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

Vaccination 40

Vaccination Vaccine Development Medicine 40

XTalks

AUGUST 8, 2022

The company has developed a proprietary discovery platform called I-ReSToRE ( RE ceptor S election and T argeting t o R einstate immune E quilibrium) that has the potential to support the development of agonist antibodies targeting immune inhibitory receptors to treat inflammatory diseases.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

XTalks

MAY 7, 2021

Novavax published the latest results from a Phase IIb clinical trial conducted in South Africa evaluating the safety and efficacy of NVX-CoV2373, appearing in the NEJM ’s May 6, 2021 issue. NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first, “original” strain of SARS-CoV-2.

Protein 97

Protein Vaccination Vaccine Trials 97

XTalks

FEBRUARY 29, 2024

These innovative molecules are engineered by combining two or more functional domains from different proteins into a single, cohesive unit, enabling them to perform multiple biological activities simultaneously. This combination aims to increase both the response rate and the duration of these responses in patients.

Protein 94

Protein Development Clinical Trials Clinical Trials 94

XTalks

NOVEMBER 30, 2023

The safety and efficacy of Cabenuva were established through two randomized, open-label, controlled clinical trials involving 1,182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) before initiating Cabenuva treatment. Additionally, Gag-specific CD8+ T cells demonstrated an increase of 1.7

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

pharmaphorum

FEBRUARY 25, 2021

Pandion ’s lead candidate PT101 has completed a phase 1a clinical trial backing its safety and tolerability, and is due to start a phase 1a/2b study in ulcerative colitis and a phase 2 trial in systemic lupus erythematosus before the end of the year.

Clinical Trials 71

Clinical Trials Clinical Trials Immune Response Trials 71

Advarra

JANUARY 11, 2024

After injection of such a vaccine, the mRNA instructs cells to produce proteins designed to stimulate an immune response against these same protein targets when they show up in viruses or in tumor cells. Adoptive T Cell Therapies Adoptive T cell therapy is another form of cancer treatment leveraging the patient’s immune system.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

pharmaphorum

OCTOBER 12, 2022

Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”. Debiopharm is interested in innovative therapeutic platforms for tomorrow,” Gibbs says. “We

Genome 105

Genome Genomics Medicine Development 105

Bioengineer

JULY 15, 2021

. “We’re excited–with such low doses of radiation, we didn’t expect the response to be so positive,” said lead author Ravi Patel, M.D., “In clinical trials, we tend to go with the maximum tolerable dose, the idea being that radiation kills the cancer and the more we give, the better.

Medicine 52

Medicine Clinical Trials Clinical Trials Scientist 52

Pharmaceutical Technology

MAY 2, 2023

The most widely utilised IO class is immune checkpoint inhibitors (ICIs), which work by blocking the inhibitory interactions between tumour cells and T-cells, facilitating an anti-tumour immune response. There are more than 20 marketed ICIs with approvals across a very wide spectrum of solid tumour indications.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 40

Antibody Vaccination Vaccine Trials 40

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

The Pharma Data

JUNE 17, 2022

However, immunocompromised individuals still lack effective immunity against SARS-CoV-2 infection. The first molecule being developed based on the new research, SPK001, is being studied by the biotech company SpikImm, and clinical trials are expected to start in the middle of this year.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

Roots Analysis

DECEMBER 11, 2022

Various strategies that are used to redirect T-cells in order to elicit the desired immune response are given below: Source: Roots Analysis. Post amplification engineered T-cells are washed and concentrated. For several days, the culture is expanded in the bioreactor.

Marketing 40

Marketing Production Genetics Immune Response 40

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

The Pharma Data

JANUARY 11, 2021

Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

JANUARY 17, 2021

The year is starting to pick up in terms of clinical trial announcements. Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days. Here’s a look at last week’s news.

Immune Response 52

Immune Response Antibody Trials Clinical Trials 52